Development of anti-angiogenic erlotinib liposomal formulation for pulmonary hypertension: a QbD approach
Crossref DOI link: https://doi.org/10.1007/s13346-019-00641-2
Published Online: 2019-04-18
Published Print: 2019-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Dhoble, Sagar
Patravale, Vandana
Text and Data Mining valid from 2019-04-18
Article History
First Online: 18 April 2019
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.